Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies [PDF]
Frontiers in Immunology, 2019 Heavy chain-only antibodies (HCAbs) do not associate with light chains and their VH regions are functional as single domains, forming the smallest active antibody fragment.
Starlynn C. Clarke +21 more
doaj +7 more sources
Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer [PDF]
International Journal of Molecular Sciences, 2021 Building upon the resounding therapeutic success of monoclonal antibodies, and supported by accelerating progress in engineering methods, the field of multispecific therapeutic antibodies is growing rapidly. Over 140 different molecules are currently in clinical testing, with excellent results in recent phase 1–3 clinical trials for several of them ...
Petros Christopoulos +1 more
exaly +5 more sources
Toward Drug-Like Multispecific Antibodies by Design [PDF]
International Journal of Molecular Sciences, 2020 The success of antibody therapeutics is strongly influenced by their multifunctional nature that couples antigen recognition mediated by their variable regions with effector functions and half-life extension mediated by a subset of their constant regions.
Peter M Tessier, Tessier Peter M
exaly +5 more sources
Bispecific and multispecific immune engagers for redirecting innate and adaptive immunity against hematologic cancers [PDF]
Discover OncologyBispecific antibodies (BsAbs) and multispecific antibodies (MsAbs) represent a transformative class of immunotherapeutics in oncology. These engineered molecules possess the unique ability to simultaneously target two or more distinct antigens, thereby ...
Mustafa T. Ardah +8 more
doaj +2 more sources
Differential T cell reactivation by two PD-L1 nanobodies through blockade alone or blockade with internalization [PDF]
Scientific ReportsProgrammed death-ligand 1 (PD-L1) plays a key role in tumor immune evasion by suppressing T cell activity through its interaction with programmed death-1 (PD-1).
Ji Hyun Lee +3 more
doaj +2 more sources
scFv-based biologics in diabetes: from therapeutic potential to clinical prospects [PDF]
Frontiers in ImmunologyThe global epidemic of diabetes mellitus the limitations of current therapies-including waning efficacy, adverse effects, and inability to modify disease progression-have accelerated the shift from conventional pharmacotherapy toward biologic agents ...
Shikun Ge +14 more
doaj +2 more sources
From discovery to the clinic: structural insights, engineering options, clinical, and ‘next wave’ applications of camelid-derived single-domain antibodies [PDF]
mAbsCamelid-derived single domain antibodies (sdAbs), referred to as VHHs (variable domains of the heavy chain of a heavy chain-only antibodies), recently emerged as promising building blocks for the construction of therapeutic molecules. As of October 2025,
Andreas Evers +3 more
doaj +2 more sources
The use of CrossMAb technology for the generation of bi- and multispecific antibodies. [PDF]
MAbs, 2016 The major challenge in the generation of bispecific IgG antibodies is enforcement of the correct heavy and light chain association. The correct association of generic light chains can be enabled using immunoglobulin domain crossover, known as CrossMAb technology, which can be combined with approaches enabling correct heavy chain association such as ...
Klein C, Schaefer W, Regula JT.
europepmc +4 more sources
Evolution of bispecific and multispecific antibodies in cancer therapy. [PDF]
Lancet Reg Health EurFontana E +5 more
europepmc +2 more sources
Engineered mRNA and the Rise of Next-Generation Antibodies
Antibodies, 2021 Monoclonal antibodies are widely used as therapeutic agents in medicine. However, clinical-grade proteins require sophisticated technologies and are extremely expensive to produce, resulting in long lead times and high costs.
Laura Sanz, Luis Álvarez-Vallina
doaj +1 more source